Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aclasta vs Prolia in Osteoporosis with Primary Hyperparathyroidism
NCT04085419Phase 4Unknown
- Sponsor
- University Medical Centre Ljubljana
- Start
- May 2019
- Primary completion
- May 2023
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in osteoporosis comparing Prolia Arm with Aclasta Arm (2 arms). Primary endpoints: Bone mineral density at 24 months, C-terminal telopeptide of type I collagen at 24 months and 3 more. Status: unknown.
02
Drugs
denosumabzoledronic acid
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT04085419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04085419.